5PSQ-117 Evaluation of cardiotoxicity by osimertinib in clinical practice
5PSQ-117 Evaluation of cardiotoxicity by osimertinib in clinical practice
About this item
Full title
Author / Creator
Publisher
London: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
London: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
Background and ImportanceOsimertinib is a tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small-cell lung cancer (NSCLC). Despite a better safety profile than other TKIs for the same indication, osimertinib could produce some potentially fatal cardiotoxicity. However, the available evidenc...
Alternative Titles
Full title
5PSQ-117 Evaluation of cardiotoxicity by osimertinib in clinical practice
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2808475194
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2808475194
Other Identifiers
ISSN
2047-9956
E-ISSN
2047-9964
DOI
10.1136/ejhpharm-2023-eahp.456
